NRX Pharmaceuticals, Inc. (NRXP)
NRXP moved a median of -0.03% 30 minutes after news, and -0.25% by the close. How NRXP actually reacts to news — the realized, point-in-time move the market made, measured across 309 labeled events over the last three years with zero look-ahead.
NRXP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.15% | 41% | 306 |
| 30-min | -0.03% | 45% | 309 |
| 60-min | 0.00% | 48% | 309 |
| to close | -0.25% | 47% | 305 |
| Middle 50% of NRXP reactions | -2.57% to +2.14% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 309 |
Half of all NRX Pharmaceuticals, Inc. news events land between -2.57% and +2.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NRXP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NRXP's baseline. Nothing else.
Recent NRXP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K NRX Pharmaceuticals, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine | Press release | GlobeNewswire | -0.40% | +7.12% | |
| Form 8-K NRX Pharmaceuticals, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +1.73% | |
| NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression | Press release | GlobeNewswire | -1.65% | -3.31% | |
| Form 8-K NRX Pharmaceuticals, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -1.18% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine | Press release | GlobeNewswire | +2.42% | +4.62% | |
| Form 8-K NRX Pharmaceuticals, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +3.56% | |
| GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) | Press release | GlobeNewswire | +0.89% | +3.56% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System | Press release | GlobeNewswire | -0.29% | -1.16% | |
| NRx Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.57% | -0.86% | |
| Form 8-K NRX Pharmaceuticals, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +5.16% | +10.64% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET | Press release | GlobeNewswire | +5.16% | +10.64% | |
| Form 10-Q NRX Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.16% | +10.64% | |
| FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval | Press release | GlobeNewswire | -1.45% | +3.77% | |
| Form 8-K NRX Pharmaceuticals, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | +3.77% | |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans | Press release | GlobeNewswire | +1.43% | — | |
| Form 8-K NRX Pharmaceuticals, For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | +1.59% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System | Press release | GlobeNewswire | -0.99% | +0.28% | |
| NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute | Press release | GlobeNewswire | +0.00% | +5.97% | |
| Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition | Press release | Business Wire | -0.75% | -4.81% | |
| ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics | Press release | PR Newswire | +2.10% | -1.05% | |
| NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression | Press release | GlobeNewswire | +0.75% | -2.26% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. | Press release | GlobeNewswire | -1.59% | +1.22% | |
| Form 8-K NRX Pharmaceuticals, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | +1.22% | |
| NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option | Press release | GlobeNewswire | -1.59% | +1.22% | |
| NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | -3.60% | +12.19% | |
| Form 8-K NRX Pharmaceuticals, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -3.60% | +12.19% | |
| NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -3.60% | +12.19% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 | Press release | GlobeNewswire | +2.59% | +4.47% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System | Press release | GlobeNewswire | -4.88% | -0.47% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.06% | -8.11% | |
| Form 10-Q NRX Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.06% | -8.11% | |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update | Press release | GlobeNewswire | -1.34% | +7.72% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality | Press release | GlobeNewswire | -2.30% | +0.66% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine | Press release | GlobeNewswire | +3.92% | -0.65% | |
| New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global | Press release | ACCESS Newswire | +1.84% | +1.34% | |
| NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program | Press release | GlobeNewswire | -5.26% | -2.30% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality | Press release | GlobeNewswire | +7.06% | +25.49% | |
| NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | Press release | GlobeNewswire | -3.19% | +0.40% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer | Press release | GlobeNewswire | -1.34% | +1.79% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application | Press release | GlobeNewswire | +1.80% | +1.35% | |
| Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network | Press release | GlobeNewswire | -0.69% | -4.13% | |
| Form 8-K NRX Pharmaceuticals, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +12.09% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress | Press release | GlobeNewswire | -0.27% | +13.30% | |
| Form 10-K NRX Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.27% | +13.30% | |
| NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 | Press release | GlobeNewswire | +0.00% | -0.54% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application | Press release | GlobeNewswire | -1.17% | -8.45% | |
| NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting | Press release | GlobeNewswire | +2.07% | +7.77% | |
| HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD | Press release | GlobeNewswire | +0.00% | +5.49% | |
| NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer | Press release | GlobeNewswire | -1.36% | -1.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NRXP section they belong to.
Where else NRXP is measured.
NRXP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NRX Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled NRXP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 309 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of NRXP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NRXP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.